Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shuxuening injection for acute ischemic stroke
ChiCTR1800019755Phase 4Recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Dec 2018
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of shuxuening in ischemic stroke (2 arms), sponsored by Peking University Third Hospital. Primary endpoint: Modified Rankin Scale responder rate. Started Dec 2018; status: recruiting.
02
Drugs
shuxuening
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on ChiCTR1800019755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800019755.